Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box
In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.